{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:19:03Z","timestamp":1788437943834,"version":"build-2803163510"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"Abstract:<\/jats:title>\n \n BACKGROUND:<\/jats:title>\n Schizophrenia has traditionally been conceptualized through dopaminergic and glutamatergic frameworks. In recent years, attention has increasingly focused on the role of immune dysregulation in its pathophysiology, although conclusive evidence remains limited. In this context, the present study aimed to investigate alterations in cytokine profiles and their association with clinical symptomatology following treatment with atypical antipsychotics for 8 weeks.<\/jats:p>\n <\/jats:sec>\n \n MATERIALS AND METHODS:<\/jats:title>\n Thirty patients aged 18\u201365 years, diagnosed with schizophrenia as per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria, were enrolled. Participants received atypical antipsychotic therapy as clinically indicated. Symptom severity was assessed using the Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for the Assessment of Negative Symptoms (SANS). Serum levels of tumor necrosis factor-alpha (TNF-\u03b1), interleukin-8 (IL-8), and regulated upon activation, normal T-cell expressed and secreted (RANTES) were measured at baseline and after 8 weeks of therapy.<\/jats:p>\n <\/jats:sec>\n \n RESULTS:<\/jats:title>\n \n Median SAPS and SANS scores significantly decreased from 39 to 30.5 (\n P<\/jats:italic>\n < 0.001) and from 30 to 28 (\n P<\/jats:italic>\n < 0.001), respectively. Correspondingly, median serum TNF-\u03b1 levels declined from 28.55 (6.51\u2013227) to 19.98 (4.56\u2013145) pg\/mL (\n P<\/jats:italic>\n = 0.033). Reductions were also observed for IL-8 (62.2\u201350.25 pg\/mL;\n P<\/jats:italic>\n = 0.171) and RANTES (520\u2013500 pg\/mL;\n P<\/jats:italic>\n = 0.758).\n <\/jats:p>\n <\/jats:sec>\n \n CONCLUSION:<\/jats:title>\n Treatment with atypical antipsychotics significantly attenuated both positive and negative symptoms and reduced TNF-\u03b1 levels in patients with schizophrenia. The concomitant decline in cytokine concentrations suggests a potential immunomodulatory effect of treatment, highlighting TNF-\u03b1, IL-8, and RANTES as possible prognostic biomarkers.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijp.ijp_63_26","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:00:32Z","timestamp":1788354032000},"page":"558-566","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Impact of atypical antipsychotics on cytokine profiles in schizophrenia: An 8-week longitudinal study"],"prefix":"10.4103","volume":"58","author":[{"given":"Aashima","family":"Handa","sequence":"first","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir Chandra","family":"Sarangi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. H.","family":"Reeta","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"R1-20260903","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1176\/ajp.148.11.1474","article-title":"Dopamine in schizophrenia: A review and reconceptualization","volume":"148","author":"Davis","year":"1991","journal-title":"Am J Psychiatry"},{"key":"R2-20260903","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1007\/s12035-022-02976-3","article-title":"Linking inflammation, aberrant glutamate-dopamine interaction, and post-synaptic changes: Translational relevance for schizophrenia and antipsychotic treatment: A systematic review","volume":"59","author":"de Bartolomeis","year":"2022","journal-title":"Mol Neurobiol"},{"key":"R3-20260903","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2016.09.019","article-title":"Abnormalities in chemokine levels in schizophrenia and their clinical correlates","volume":"181","author":"Hong","year":"2017","journal-title":"Schizophr Res"},{"key":"R4-20260903","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.immuni.2012.05.008","article-title":"The chemokine superfamily revisited","volume":"36","author":"Zlotnik","year":"2012","journal-title":"Immunity"},{"key":"R5-20260903","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.5694\/j.1326-5377.2003.tb05311.x","article-title":"Medical comorbidity in schizophrenia","volume":"178","author":"Lambert","year":"2003","journal-title":"Med J Aust"},{"key":"R6-20260903","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0972-6748.144953","article-title":"Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study","volume":"23","author":"Kumar","year":"2014","journal-title":"Ind Psychiatry J"},{"key":"R7-20260903","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1016\/j.bbamcr.2014.05.014","article-title":"Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease","author":"Turner","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"R8-20260903","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3389\/fpsyt.2018.00753","article-title":"Constructing the immune signature of schizophrenia for clinical use and research; an integrative review translating descriptives into diagnostics","volume":"9","author":"Kroken","year":"2018","journal-title":"Front Psychiatry"},{"key":"R9-20260903","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3371\/CSRP.MICU.020813","article-title":"C-reactive protein levels in schizophrenia: A review and meta-analysis","volume":"7","author":"Miller","year":"2014","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"R10-20260903","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0165-1781(97)00036-X","article-title":"Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: Effects of clozapine treatment","volume":"71","author":"Monteleone","year":"1997","journal-title":"Psychiatry Res"},{"key":"R11-20260903","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00213-013-3382-4","article-title":"Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug na\u00efve, first-episode schizophrenia","volume":"231","author":"Song","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"R12-20260903","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bbi.2018.05.002","article-title":"Profiling inflammatory signatures of schizophrenia: A cross-sectional and meta-analysis study","volume":"71","author":"Frydecka","year":"2018","journal-title":"Brain Behav Immun"},{"key":"R13-20260903","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neubiorev.2014.02.001","article-title":"Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: A systematic review of biomarker studies","volume":"42","author":"Stuart","year":"2014","journal-title":"Neurosci Biobehav Rev"},{"key":"R14-20260903","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4088\/JCP.10m06349","article-title":"Time to treatment response in first-episode schizophrenia: Should acute treatment trials last several months?","volume":"72","author":"Gallego","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"R15-20260903","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3389\/fpsyt.2019.00892","article-title":"Cytokine alterations in schizophrenia: An updated review","volume":"10","author":"Momtazmanesh","year":"2019","journal-title":"Front Psychiatry"},{"key":"R16-20260903","first-page":"200","article-title":"Serum TNF-\u03b1, IL-10 and IL-2 in schizophrenic patients before and after treatment with risperidone and clozapine","volume":"11","author":"Ajami","year":"2014","journal-title":"Iran J Immunol"},{"key":"R17-20260903","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.psychres.2018.08.002","article-title":"Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study)","volume":"268","author":"Strzelecki","year":"2018","journal-title":"Psychiatry Res"},{"key":"R18-20260903","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2202-12-13","article-title":"Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls","volume":"12","author":"Reale","year":"2011","journal-title":"BMC Neurosci"},{"key":"R19-20260903","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/10673229409017120","article-title":"Immune abnormalities in schizophrenia: Evidence for the autoimmune hypothesis","volume":"2","author":"Ganguli","year":"1994","journal-title":"Harv Rev Psychiatry"},{"key":"R20-20260903","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.neuropharm.2016.05.020","article-title":"The kynurenine pathway in schizophrenia and bipolar disorder","volume":"112","author":"Erhardt","year":"2017","journal-title":"Neuropharmacology"},{"key":"R21-20260903","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2022.02.008","article-title":"Editorial for special issue: From cytokines to climate and C-sections and from micronutrients to the microbiome: Neurodevelopment and the risk for psychosis","volume":"247","author":"Malaspina","year":"2022","journal-title":"Schizophr Res"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_63_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:04:06Z","timestamp":1788437046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_63_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_63_26","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-01-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}